In ovarian cancer, the activation of NLRP3‐induced pyroptosis can inhibit ovarian cancer progression.[43] In hepatocellular carcinoma cells, Shuanghua decoction exerts anticancer activity by activating NLRP3 inflammasome.[44] In cervical cancer, targeting Foxm1 mediates the activation of NLRP3 inflammasome and stimulates CD8+ T cell antitumor immunity.[45] Our results suggest that HTR2B might influence osteosarcoma progression through the NLRP3 inflammasome pathway. The gene discussed is CD8A; the disease is ovarian carcinoma.